ProShare Advisors’s Harvard Bioscience HBIO Stock Holding History

ProShare Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,148	Closed	-$24.2K	–	2155
2024 Q4	$24.2K	Buy	+1,148	New	+$26.4K	﹤0.01%	2248
2022 Q2	–	Sell	-1,159	Closed	-$72K	–	1937
2022 Q1	$72K	Sell	1,159 -274	-19%	-$16.2K	﹤0.01%	2081
2021 Q4	$101K	Buy	+1,433	New	+$102K	﹤0.01%	2204
2021 Q2	–	Sell	-1,023	Closed	-$56K	–	2384
2021 Q1	$56K	Buy	+1,023	New	+$49.8K	﹤0.01%	2220
2014 Q2	–	Sell	-2,582	Closed	-$122K	–	2517
2014 Q1	$122K	Buy	+2,582	New	+$118K	﹤0.01%	2652
2013 Q4	–	Sell	-2,136	Closed	-$85K	–	1562
2013 Q3	$85K	Buy	2,136 +27	+1%	+$1.06K	﹤0.01%	2453
2013 Q2	$76K	Buy	+2,109	New	+$80.7K	﹤0.01%	2311

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's HBIO Position: Q1 2025 in Review

ProShare Advisors sold out of Harvard Bioscience (HBIO) in Q1 2025, closing a stake of 1,148 shares — an estimated $24.2K sold.

ProShare Advisors first reported a position in HBIO in Q2 2013 and held it in 7 quarters. The position peaked at $122K in Q1 2014. 91 funds tracked by Wall St. Rank hold HBIO as of Q1 2025.

ProShare Advisors reported no remaining Harvard Bioscience position as of Q1 2025 after selling out during the quarter.
ProShare Advisors sold 1,148 Harvard Bioscience shares in Q1 2025, an estimated $24.2K.
ProShare Advisors first reported a position in Harvard Bioscience in Q2 2013 and held it in 7 quarters.
ProShare Advisors's Harvard Bioscience position peaked at $122K in Q1 2014.
91 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.